Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?

Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.

MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies).

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The global prevalence of dAMD is 266 million worldwide, and GA affects approximately 2-3 million people in the United States (U.S.) and Europe. Importantly, this number is expected to increase significantly as populations age.

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026.

Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.

Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.